Bio-Rad reported a 27.1% year-over-year increase in net sales to $726.8 million for the first quarter of 2021, driven by strong demand for COVID-19-related products. Excluding COVID-19-related sales of $94 million, revenue increased by 23.4% on a currency-neutral basis. Despite operational challenges posed by the pandemic, Bio-Rad adapted well and continued to meet customer demand. The company's non-GAAP diluted earnings per share surged 173% to $5.21, while the non-GAAP operating margin expanded significantly to 25.8% from 13.9% in Q1 2020. Bio-Rad anticipates continued COVID-19 sales in the range of $170 million to $180 million for the full year and projects currency-neutral revenue growth between 5.5% and 6%, with a non-GAAP operating margin of approximately 17%.